WallStreetZen

AnalystsKeay Nakae
Keay Nakae's Stock Forecasts

Ranking
Top 1%
#8 out of 3514 analysts
Average Return
+277.47%
Win Rate
55%11 out of 20
Risk vs Reward
Poor
Good

Keay Nakae's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Ocugen IncOCGN
+5,554.71%$0.22$12.61
2020-06-03 -
2021-02-09
Strong Buy
CareCloud IncMTBC
+104.17%$2.40$4.90
2017-11-14 -
2018-11-14
Strong Buy
Arrowhead Pharmaceuticals IncARWR
+62.51%$19.39$31.51
2018-09-06 -
2019-09-06
Strong Buy
Mesoblast LtdMESO
+56.15%$16.10$7.06
2020-12-04 -
2021-07-29
Strong Sell
Emergent BioSolutions IncEBS
+30.93%$78.70$103.04
2020-05-01 -
2021-02-19
Strong Buy

Keay Nakae's Stock Coverage

Name / Ticker# of RatingsRatingPrice TargetUpside/DownsideActionDate
Seres Therapeutics IncMCRB
1Strong Buy$16.00-55.63%Maintains
9 days ago
Femasys IncFEMY
1Strong Buy$25.00-70.80%Initiates Coverage On
19 days ago
Axcella Health IncAXLA
1Strong Buy$10.00-66.00%Maintains
2 months ago
Emergent BioSolutions IncEBS
5Strong Buy$92.00-28.37%Maintains
3 months ago
Dicerna Pharmaceuticals IncDRNA
1Strong Buy$34.00+10.32%Maintains
5 months ago
Ocugen IncOCGN
2Hold$13.00-48.38%Downgrades
6 months ago
Arrowhead Pharmaceuticals IncARWR
2Strong Buy$97.00-28.57%Maintains
6 months ago
Mesoblast LtdMESO
1Strong Sell$7.50-6.67%Downgrades
8 months ago
1HoldN/AN/ADowngrades
9 months ago
Sonnet BioTherapeutics Holdings IncSONN
2Strong Buy$8.00-86.75%Maintains
a year ago
OncoCyte CorpOCX
1Hold$2.00N/ADowngrades
a year ago
NeuBase Therapeutics IncNBSE
2Strong Buy$18.00N/AMaintains
a year ago
Arbutus Biopharma CorpABUS
1Strong Buy$5.00N/AUpgrades
a year ago
Caladrius Biosciences IncCLBS
1Strong Buy$7.00N/AMaintains
3 years ago
CareCloud IncMTBC
1Strong Buy$2.75N/AMaintains
4 years ago
Biocept IncBIOC
1Strong Buy$2.50N/AInitiates Coverage On
4 years ago
1Strong Buy$6.50N/AInitiates Coverage On
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.